Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($) $ in Millions		3 Months Ended		6 Months Ended
		Jul. 03, 2022	Jul. 04, 2021	Jul. 03, 2022	Jul. 04, 2021
Fair Value Disclosures [Abstract]
Net (gains)/losses recognized during the period on equity securities	[1],[2]	$ 541	$ (800)	$ 1,241	$ (1,200)
Less: Net (gains)/losses recognized during the period on equity securities sold during the period		(68)	24	(79)	(5)
Net unrealized (gains)/losses during the reporting period on equity securities still held at the reporting date	[3]	$ 610	$ (823)	$ 1,320	$ (1,196)

[1] Reported in Other (income)/deductions––net. See Note 4.

[2] The losses in the second quarter and first six months of 2022 include, among other things, unrealized losses of $432 million and $776 million, respectively, related to investments in BioNTech and Cerevel Therapeutics Holdings, Inc. (Cerevel). The gains in the second quarter and first six months of 2021 included, among other things, unrealized gains of $917 million and $1.0 billion, respectively, related to investments in BioNTech and Cerevel.

[3] Included in net unrealized (gains)/losses are observable price changes on equity securities without readily determinable fair values. As of July 3, 2022, there were cumulative impairments and downward adjustments of $108 million and upward adjustments of $194 million. Impairments, downward and upward adjustments were not significant in the second quarter and first six months of 2022 and 2021.